Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cell Genesys
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of adenocarcinoma prostate cancer
Prostate cancer deemed to be unresponsive or refractory to hormone therapy
An ECOG performance status of 0 or 1
You may not be if
Transitional cell, small cell, neuroendocrine, or squamous cell prostate cancer
Previous chemotherapy, biological or immunotherapy for cancer
Previous gene therapy for cancer
Significant cancer related pain
Clareo Health | Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer
